The Alzheimer’s Association has granted 3$ million to Longeveron, a biotechnology company focused on treating age-related diseases, to fund their Phase I clinical trial, which utilizes mesenchymal stem cells to treat the chronic inflammation that has been associated with the development of Alzheimer’s disease. Mesenchymal stem cells, known for their immunomodulatory and anti-inflammatory properties, are ideal candidates to treat areas of inflammation, as other studies have already successfully shown their efficacy in regulating this condition.
Treatments like this underscore how health and longevity are becoming a focus in regenerative medicine, and how stem cell treatments are likely to have an outsized impact on expanding patients’ healthspans. Since neurodegenerative diseases primarily affect older individuals, having younger stem cells available for treatments later in life will allow patients to have more effective treatment options.
With clinical trials underway, this advancement in bioengineering will accelerate this trend and broaden applications to treat a wider variety of neurodegenerative diseases. By banking their own valuable stem cells, families can ensure that they will have access to emerging regenerative therapies. To learn more about banking stem cells, please visit StemSave or call 877-783- 6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.